PH24873A - Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent - Google Patents

Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent

Info

Publication number: PH24873A
Authority: PH; Philippines
Prior art keywords: dione; thiazolidine; benzopyran; dihydro; benzyl
Prior art date: 1987-12-02

Application number

PH37884A

Other languages

English (en)

Inventor

Michael Norman Krupp

Archie Calhoun Swindell

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-02

Filing date

1988-12-02

Publication date

1990-12-26

1988-12-02 Application filed by Pfizer filed Critical Pfizer

1990-12-26 Publication of PH24873A publication Critical patent/PH24873A/en

Links

ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title abstract 4
241000124008 Mammalia Species 0.000 abstract 3
-1 2-benzyl-3,4-dihydro-2H-benzopyran-6-yl Chemical group 0.000 abstract 2
125000002091 cationic group Chemical group 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
200000000007 Arterial disease Diseases 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
230000000979 retarding effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

PH37884A 1987-12-02 1988-12-02 Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent PH24873A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/127,858 US4798835A (en)	1987-12-02	1987-12-02	dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent

Publications (1)

Publication Number	Publication Date
PH24873A true PH24873A (en)	1990-12-26

Family

ID=22432331

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH37884A PH24873A (en)	1987-12-02	1988-12-02	Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent

Country Status (16)

Country	Link
US (1)	US4798835A (de)
EP (1)	EP0319288B1 (de)
JP (1)	JPH01186883A (de)
KR (1)	KR900006993B1 (de)
AT (1)	ATE81456T1 (de)
AU (1)	AU604176B2 (de)
CA (1)	CA1313139C (de)
DE (1)	DE3875324T2 (de)
DK (1)	DK670988A (de)
HU (1)	HU204433B (de)
IE (1)	IE883600L (de)
IL (1)	IL88513A (de)
MY (1)	MY103498A (de)
PH (1)	PH24873A (de)
PT (1)	PT89123B (de)
ZA (1)	ZA888968B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5053420A (en) *	1989-10-13	1991-10-01	Pershadsingh Harrihar A	Thiazolidine derivatives for the treatment of hypertension
ES2092539T3 (es) *	1991-01-10	1996-12-01	Transcend Therapeutics Inc	Uso de derivados de la tiazolidina-4-carboxilato para el tratamiento de enfermedades pulmonares.
US5747459A (en) *	1991-02-04	1998-05-05	Nestec, Ltd.	Method for insuring adequate intracellular glutathione in tissue
US5866595A (en) *	1991-09-26	1999-02-02	The Regents Of The University Of California	Calcium antagonists for treatment of vascular restenosis
US5430045A (en) *	1992-04-23	1995-07-04	Free Radical Sciences, Inc.	Method of reducing or preventing bone marrow hypoplasia
US5306724A (en) *	1992-08-17	1994-04-26	Clintec Nutrition Company	Method for preventing and treating atherosclerosis
US5447712A (en) *	1993-12-09	1995-09-05	Free Radical Sciences	Method of reducing cyclophosphamide induced hemorrhagic cystitis
GB9611947D0 (en) *	1996-06-07	1996-08-07	Glaxo Group Ltd	Medicaments

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5522636A (en) *	1978-08-04	1980-02-18	Takeda Chem Ind Ltd	Thiazoliding derivative
JPS58118577A (ja) *	1982-01-07	1983-07-14	Takeda Chem Ind Ltd	チアゾリジン誘導体
US4617312A (en) *	1983-01-17	1986-10-14	Pfizer Inc.	Aldose reductase inhibiting 5-(2-alkoxyphenyl) thiazolidinediones
JPS6051189A (ja) *	1983-08-30	1985-03-22	Sankyo Co Ltd	チアゾリジン誘導体およびその製造法
AR240698A1 (es) *	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
HU210339B (en) *	1985-05-21	1995-03-28	Pfizer	Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) *	1985-06-10	1994-01-05	武田薬品工業株式会社	チアゾリジオン誘導体およびそれを含んでなる医薬組成物

1987
- 1987-12-02 US US07/127,858 patent/US4798835A/en not_active Expired - Lifetime
1988
- 1988-11-26 MY MYPI88001364A patent/MY103498A/en unknown
- 1988-11-28 IL IL8851388A patent/IL88513A/en unknown
- 1988-11-29 JP JP63302127A patent/JPH01186883A/ja active Granted
- 1988-11-30 PT PT89123A patent/PT89123B/pt not_active IP Right Cessation
- 1988-11-30 ZA ZA888968A patent/ZA888968B/xx unknown
- 1988-11-30 CA CA000584530A patent/CA1313139C/en not_active Expired - Fee Related
- 1988-12-01 EP EP88311378A patent/EP0319288B1/de not_active Expired - Lifetime
- 1988-12-01 DK DK670988A patent/DK670988A/da not_active Application Discontinuation
- 1988-12-01 HU HU886143A patent/HU204433B/hu not_active IP Right Cessation
- 1988-12-01 AT AT88311378T patent/ATE81456T1/de not_active IP Right Cessation
- 1988-12-01 AU AU26471/88A patent/AU604176B2/en not_active Ceased
- 1988-12-01 IE IE883600A patent/IE883600L/xx unknown
- 1988-12-01 DE DE8888311378T patent/DE3875324T2/de not_active Expired - Fee Related
- 1988-12-01 KR KR1019880015992A patent/KR900006993B1/ko not_active Expired
- 1988-12-02 PH PH37884A patent/PH24873A/en unknown

Also Published As

Publication number	Publication date
ATE81456T1 (de)	1992-10-15
IL88513A0 (en)	1989-06-30
PT89123A (pt)	1989-12-29
IE883600L (en)	1989-06-02
US4798835A (en)	1989-01-17
DE3875324T2 (de)	1993-02-25
AU604176B2 (en)	1990-12-06
HUT54045A (en)	1991-01-28
AU2647188A (en)	1989-06-08
CA1313139C (en)	1993-01-26
PT89123B (pt)	1993-09-30
DK670988D0 (da)	1988-12-01
EP0319288A3 (en)	1990-12-27
JPH01186883A (ja)	1989-07-26
ZA888968B (en)	1990-07-25
DK670988A (da)	1989-07-24
JPH0460582B2 (de)	1992-09-28
DE3875324D1 (de)	1992-11-19
EP0319288A2 (de)	1989-06-07
IL88513A (en)	1994-04-12
MY103498A (en)	1993-06-30
EP0319288B1 (de)	1992-10-14
HU204433B (en)	1992-01-28
KR900006993B1 (ko)	1990-09-25
KR890009922A (ko)	1989-08-04

Similar Documents

Publication	Publication Date	Title
MX9203808A (es)	1992-07-01	Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
DE3668892D1 (en)	1990-03-15	Hypoglycemische thiazolidinedione.
MY121517A (en)	2006-01-28	Anticonvulsant derivatives useful in reducing blood glucose levels
AU1578688A (en)	1988-11-04	Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
IE802661L (en)	1981-06-18	Isoquinoline acetic acids
PH24873A (en)	1990-12-26	Dl-5((2-benzyl-3,4-dihydro=2h-benzopyran-6-yl)-methyl)thiazolidine-2,4-dione as an antiartherosclerosis agent
NO167285C (no)	1991-10-23	Analogifremgangsmaate ved fremstilling av terapeutisk aktive nafto(1,2-b)-1,4-tiazepinon-derivater.
PT87197A (pt)	1988-05-01	Processo para preparacao de agentes terapeuticos eritropoietina
GB2191695B (en)	1990-11-28	An ophthalmic pharmaceutical composition for cataract
DZ2430A1 (fr)	2003-01-11	Procédé pour la préparation de dérivés de thiazolidinedione substitués.
AU1083488A (en)	1988-07-15	Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus
KR900009647A (ko)	1990-07-05	아데노신 유도체, 그들의 제법 및 사용방법
EP0292352A3 (de)	1988-12-28	Makrolid-Derivate, Verfahren zu ihrer Herstellung und ihre pharmazeutischen Zusammensetzungen
NO905364L (no)	1991-06-14	Fremgangsmaate ved fremstilling av alkansyrederivater.
AU7935887A (en)	1988-04-14	Therapeutic agent for the treatment of peptic ulcer disease
FR2696745B1 (fr)	1995-05-12	Procédé de préparation de dérivés de phényltétrazole.
EP0378146A3 (de)	1991-04-24	Polyamin-Derivate als antineoplastische Mittel
NO880922D0 (no)	1988-03-02	Fremgangsmaate for fremstilling av farmakologisk aktive benzodioksolderivater.
WO1999021538A3 (de)	1999-08-05	Verwendung von glykosaminoglykanen zur herstellung von pharmazeutischen zubereitungen zur behandlung von mit diabetes assoziierten augenkrankheiten
DE69006662D1 (de)	1994-03-24	Insulinzubereitung für nicht-parenterale Verabreichung.
NO166789C (no)	1991-09-04	Analogifremgangsmaate for fremstilling av terapeutisk aktiv kalsium-10-propyl-2,8-bis(1h-tetrazol-5-yl)-4h, 6h-benzo(1,2-b;5,4-b')di-pyran-4,6-dion.
NO891996L (no)	1990-11-19	Forbedret fremgangsmaate for fremstilling av 3-((4-brom-2-fluorfenyl)-methyl)-3, 4-dihydro-4-oxo-l-fthalazin-eddiksyre.
FI880684A7 (fi)	1988-08-13	Menetelmä parenteraalisesti annettavien verituotteiden valmistamiseksi
FR2716196B1 (fr)	1996-04-05	Dérivés de 8-[2-(1H-tétrazol-5-yl) phényl] quinoléine, leur préparation et leur application en thérapeutique.
ATE91893T1 (de)	1993-08-15	Mitonafide-infusionsloesung.